|
|
|
|
Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG
Igeneon was one of the largest Austrian biotech firms, developing cancer vaccines and immunotherapies. GCP co-invested in the B and C-rounds in a syndicate led by 3i and DVCG and had observer status in the board. In December 2004, Igeneon merged with then NASDAQ quoted Aphton Corporation to create a diversified global immunotherapy company and access US capital markets. Aphton filed for bankruptcy in May 2006, Igeneon followed in August 2006. GCP fully wrote off the investment in 2006.
Contact
igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG (Aphton Corp.)
Brunner Straße 69, Obj. 3
A-1230 Vienna
www.igeneon.com and www.aphton.com
News
News about Igeneon
Reisnerstrasse 40/3
A-1030 Vienna
Tel.: +43 (1) 513 10 72
Fax: +43 (1) 513 10 72-200
office@gamma-capital.com
www.gamma-capital.com